Isabel R. Preeshagul

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study”.

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

The Lancet(2023)10.1016/s0140-6736(23)01857-3

N/A

4.7DataRank · unranked

264 citations

Jonathan T. Yang, Juber Patel, Annemarie F. Shepherd, Juliana Eng, Randy Yeh +44 more

COVID-19 in patients with lung cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.06.007

N/A

0.840DataRank · unranked

270 citations

Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chai Bandlamudi +26 more

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Nature Medicine(2022)10.1038/s41591-022-02047-z

N/A

0.792DataRank · unranked

195 citations

Emily S. Lebow, Randy Yeh, Jeeban Paul Das, Azadeh Namakydoust, Paul K. Paik +67 more

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3418

N/A

0.723DataRank · unranked

123 citations

Barzin Y. Nabet, Hira Rizvi, Aadel A. Chaudhuri, Daniel K. Wells, Mark Dunphy +30 more

Acquired resistance to PD-1 blockade in NSCLC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9621

N/A

0.425DataRank · unranked

16 citations

Hira Rizvi, Danish Memon, Jia Luo, Isabel R. Preeshagul, Jennifer L. Sauter +5 more

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006994

N/A

0.416DataRank · unranked

15 citations

Joao V. Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation

Radiotherapy and Oncology(2023)10.1016/j.radonc.2023.109983

N/A

0DataRank · unranked

9 citations

Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase +12 more

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3484

N/A

0DataRank · unranked

2 citations

Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal +9 more

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0596

N/A

0DataRank · unranked

241 citations

Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann +1 more

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer

Annals of Translational Medicine(2020)10.21037/atm-20-3982

N/A

0DataRank · unranked

1 citations

Isabel R. Preeshagul, Narek Shaverdian, Abraham J. Wu, Daphna Y. Gelblum, Daniel R. Gomez +3 more

Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab

Radiotherapy and Oncology(2021)10.1016/j.radonc.2021.12.016

N/A

0DataRank · unranked

21 citations

Annemarie F. Shepherd, Isabel R. Preeshagul, Michael Offin, Daphna Y. Gelblum, Abraham J. Wu +9 more

Ramucirumab-related osteonecrosis of the jaw

Oral Oncology(2021)10.1016/j.oraloncology.2021.105660

N/A

0DataRank · unranked

8 citations

Andrew Marco Pischek, Joseph R. Randazzo, Joseph M. Huryn, Cherry L. Estilo, Isabel R. Preeshagul +2 more

Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study

medRxiv(2022)10.1101/2022.12.05.22283131

N/A

0DataRank · unranked

0 citations

Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more